PPARG and thymus neoplasm: Furthermore, PPARγ-MG KOs had a significant ~4-fold decrease in thymic tumour incidence compared to PPARγ-WT mice in the DMBA Only-treated group (10 ± 5% vs. 40 ± 10%, respectively; p < 0.05).